[1]王 磊,周枫叶,姜春菲,等.HPLC-MS/MS法测定白血病患者血浆伊马替尼与达沙替尼浓度[J].现代检验医学杂志,2016,31(01):128-131.[doi:10.3969/j.issn.1671-7414.2016.01.037]
　WANG Lei,ZHOU Feng-ye,JIANG Chun-fei,et al.Determination of Imatinib and Dasatinib in Leukemia Patients Plasma by HPLC-MS/MS[J].Journal of Modern Laboratory Medicine,2016,31(01):128-131.[doi:10.3969/j.issn.1671-7414.2016.01.037]
点击复制

HPLC-MS/MS法测定白血病患者血浆伊马替尼与达沙替尼浓度()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第31卷
期数:
2016年01期
页码:
128-131
栏目:
研究简报·实验技术
出版日期:
2016-01-25

文章信息/Info

Title:
Determination of Imatinib and Dasatinib in Leukemia Patients Plasma by HPLC-MS/MS
作者:
王 磊1; 周枫叶1; 姜春菲1; 陶蓓蓓2; 刘红星1
1.河北燕达医院陆道培血液肿瘤中心, 河北三河 065201; 2.北京化学化工大学分析测试中心,北京 100029
Author(s):
WANG Lei1; ZHOU Feng-ye1; JIANG Chun-fei1; TAOBei-bei2; LIU Hong-xing1
1.Lu Daopei Hematology and Oncology Center,Yanda Hospital of Hebei Province,Hebei Sanhe 0655201,China; 2.Beijing University of Chemical Analysis and Test Center,Beijing 100029,China
关键词:
达沙替尼;  伊马替尼;  液质联用;  治疗药物监测
分类号:
R557; R969
DOI:
10.3969/j.issn.1671-7414.2016.01.037
文献标志码:
A
摘要:
目的 建立测定慢性粒细胞白血病(CML)患者血浆伊马替尼与达沙替尼浓度的HPLC-MS/MS法,并应用于临床治疗药物监测,为临床合理用药提供可靠依据。方法 血浆经甲醇沉淀蛋白处理,采用外标法定量。色谱柱为Ultimate XB-C18,柱温65℃,流动相为含0.1 ml/dl甲酸和2 mmol/L乙酸铵的水和含0.1ml/dl甲酸的甲醇,梯度洗脱。质谱检测方式为电喷雾离子阱正离子模式,MRM扫描,监测伊马替尼m/z 494.5>394.3,达沙替尼m/z 488.3>401.3。结果 伊马替尼浓度在0.05～7.5 μg/ml范围内与峰面积线性关系良好,Y=5.6×105X+5×103(R=0.999 8)。达沙替尼浓度在5～250 ng/ml范围内与峰面积线性关系良好,Y=211X+66.6(R=0.999 6); 日内及日间RSD均小于10%,平均回收率为96%～105%。结论 该方法简便、准确、快速,检测的特异度及灵敏度高,适用于血浆伊马替尼与达沙替尼血药浓度测定。
Abstract:
Objective To develop a HPLC-MS/MS method for determination of Imatinib and Dasatinib in CML patient,and make it used in clinic trial.Methods The separation was performed on a Ultimate XB-C18 column with a mobile phase of water(containing 2 mmol/L ammonium acetate and 0.1 ml/dl formic acid)and methanol(containing 0.1 ml/dl formic acid).The way of eluting was gradient.Mass spectrum detection method was ESI positive ion mode and monitoring Imatinib m/z 494.5>394.3 and Dasatinib m/z 488.3>401.3.Results The standard curve of Imatinib was linearover the range of 0.05～7.5 μg/ml,Y=5.6×105X+5×103(R=0.999 8).Thestandard curve of Dasatinib was linear over the range of 5～250 ng/ml,Y=211X+66.6(R=0.999 6).The relative recovery was among the range of 90%～107%.RSDsof intra-and inter-day validation were less than 10%.ConlusionThis method is convenient,accurate and rapid,and can be used for the determination of Imatinib and Dasatinib in clinic test.

参考文献/References:

[1] Agrawal M,Garg RJ,Cortes J,et al.Tyrosine kinase inhibitors:the first decade[J].Curr Hematol Malig Rep,2010,5(2):70-80.
[2] Le Coutre P,Schwarz M,Kim TD.New developments in tyrosine kinase inhibitor therapy for newly diagnosed chronic myeloid leukemia[J].Clin Cancer Res,2010,16(6):1771-1780.
[3] Saglio G,Baccarani M.First-line therapy for chronic myeloid leukemia:new horizons and an update[J].Clin Lymphoma Myeloma Leuk,2010,10(3):169-176.
[4] Redaelli S,Piazza R,Rostagno R,et al.Activity of bosutinib,dasatinib,and nilotinib against 18 imatinib-resistant BCR/ABL mutants[J].J Clin Oncol,2009,27(3):469-471.
[5] Vajpai N,Strauss A,Fendrich G,et al.Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib/nilotinib and dasatinib[J].J Biol Chem,2008,283(26):18292-18302.
[6] Kantarjian H,Shah NP,Hochhaus A,et al.Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia[J].N Engl J Med,2010,362(24):2260-2270.
[7] Cortes JE,Jones D,O'Brien S,et al.Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia[J].J Clin Oncol,2010,28(3):398-404.
[8] Shah NP,Cortes JE,Schiffer CA,et al.Four-year follow-up of patientswith chronic-phase chronic myeloid leukemia(CP-CML)receiving 100 mg of dasatinib once daily[J].J Clin Oncol,2010,28(15):6512.
[9] Masiello D,Gorospe G,Yang AS.The occurrence and management of fluid retention associated with TKI therapy in CML,with a focus on dasatinib[J].J Hematol Oncol,2009,2(20):46.
[10] Atallah E,Durand JB,Kantarjian H,et al.Congestive heart failure is a rare event in patients receiving imatinib therapy[J].Blood,2007,110(4):1233-1237.
[11] Breccia M,Cannella L,Frustaci A,et al.Cardiac events in imatinib mesylate-treated chronic myeloid leukemia patients:A single institution experience[J].Leuk Res,2008,32(5):835-836.
[12] Gratacap MP,Martin V,Valera MC,et al.The new tyrosine-kinase inhibitor and anticancer drug dasatinib reversibly affects platelet activation in vitro and in vivo[J].Blood,2009,114(9):1884-1892.

相似文献/References:

[1]苗玉迪a,魏绪仓b.达沙替尼联合氟达拉滨对慢粒K562细胞的抑制作用研究[J].现代检验医学杂志,2015,30(05):70.[doi:10.3969/j.issn.1671-7414.2015.05.021]
　MIAO Yu-dia,WEI Xu-cangb.Study on Inhibition of Dasatinib and Fludarabine to CML K562 Cells[J].Journal of Modern Laboratory Medicine,2015,30(01):70.[doi:10.3969/j.issn.1671-7414.2015.05.021]
[2]陈 静,鞠 镇.一代和二代酪氨酸激酶抑制剂治疗 对CML染色体的影响及疗效[J].现代检验医学杂志,2015,30(01):91.[doi:10.3969/j.issn.1671-7414.2015.01.025]
　CHEN Jing,JU Zhen.Chromosome's Influence and Curative Effect on First and Second Generation Tyrosine Kinase Inhibitor Therapy to CML[J].Journal of Modern Laboratory Medicine,2015,30(01):91.[doi:10.3969/j.issn.1671-7414.2015.01.025]

备注/Memo

备注/Memo:
作者简介:王 磊(1984-),男,硕士,药师,主要从事医院药学研究工作,E-mail:rosie1982@163.com。 通讯作者:刘红星,男,硕士,执业医师,主要从事检验医学研究工作。
更新日期/Last Update: 2016-01-20